Insulet Corporation

Insulet Corporation (NASDAQ: PODD) is an innovative medical device company dedicated to making the lives of people with diabetes easier. Through its OmniPod Insulin Management System, Insulet seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes. The OmniPod is a revolutionary and easy-to-use tubeless insulin pump that features just two parts and a fully-automated cannula insertion. Insulet's Delivery Systems business also partners with global pharmaceutical and biotechnology companies to tailor the OmniPod technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas.

 Founded in 2000, Insulet Corporation is based in Billerica, Massachusetts.

Company Growth (employees)
Billerica, US
Size (employees)
640 (est)
Insulet Corporation was founded in 2000 and is headquartered in Billerica, US

Insulet Corporation Office Locations

Insulet Corporation has offices in Billerica, Denver, Tulsa, Washington and in 11 other locations
Billerica, US (HQ)
200 600 Technology Park Dr
Show all (15)

Insulet Corporation Financials and Metrics

Insulet Corporation Financials

Insulet Corporation's revenue was reported to be $367 m in FY, 2016

Revenue (Q2, 2017)

109.8 m

Gross profit (Q2, 2017)

64.6 m

Gross profit margin (Q2, 2017), %


Net income (Q2, 2017)

(7.8 m)

EBIT (Q2, 2017)

(3.4 m)

Market capitalization (11-Dec-2017)

4.1 b

Cash (30-Jun-2017)

73.5 m
Insulet Corporation's current market capitalization is $4.1 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016


247.1 m288.7 m324.2 m367 m

Revenue growth, %


Cost of goods sold

134.7 m145.4 m176.1 m155.9 m

Gross profit

112.4 m143.3 m148.2 m211.1 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


61.1 m69.2 m72 m75 m61.2 m75.6 m87.3 m81.2 m87.3 m94.9 m101.7 m109.8 m

Cost of goods sold

33.7 m36.4 m36.2 m36.9 m28.4 m41.2 m51.7 m37.2 m36.9 m39.2 m42.3 m45.1 m

Gross profit

27.4 m32.8 m35.8 m38 m32.8 m34.4 m35.7 m44.1 m50.5 m55.6 m59.4 m64.6 m

Gross profit Margin, %

USDFY, 2013FY, 2014FY, 2015FY, 2016


149.7 m151.2 m122.7 m137.2 m

Accounts Receivable

33.1 m39.9 m48.4 m28.8 m


9.5 m13.1 m5.7 m35.5 m

Current Assets

198.2 m208.2 m190.8 m370 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


153.9 m145.6 m175.5 m146.4 m145.6 m145.1 m145.5 m111.6 m75.7 m215.4 m76 m73.5 m

Accounts Receivable

34.5 m36.7 m41.8 m47.1 m36.1 m31.8 m31.8 m40.5 m38.7 m38.5 m40.6 m37.8 m


5.4 m10.4 m8.8 m9.7 m20.1 m23.4 m13 m14 m24.5 m32.7 m34.3 m34 m

Current Assets

199.7 m199.9 m231.8 m206.6 m205.4 m203.8 m194.3 m171.8 m181.3 m361.8 m337.2 m338.7 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(45 m)(51.5 m)(73.5 m)(28.9 m)

Depreciation and Amortization

11.8 m12.2 m15.8 m13.8 m

Accounts Receivable

(4.5 m)(10 m)(9.8 m)12.6 m


5.4 m(3.6 m)(722 k)(24.1 m)
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(42.5 m)(6.1 m)(35.3 m)(46.1 m)(11.8 m)(27.3 m)(46.2 m)(12.5 m)(16.7 m)(19.8 m)(10 m)(17.7 m)

Depreciation and Amortization

8.9 m3.1 m6.1 m9.2 m3.4 m7.1 m11.4 m3.4 m6.8 m10.5 m3.3 m6.7 m

Accounts Receivable

(5.1 m)(4.5 m)(10.5 m)(16.7 m)3.5 m6.9 m5.3 m2.3 m3.7 m3 m(12.1 m)(9.6 m)


9.5 m(985 k)699 k(198 k)(7 m)(10.3 m)312 k(2.6 m)(13.1 m)(21.3 m)1.2 m1.5 m
Y, 2017

Financial Leverage

7.1 x
Show all financial metrics

Insulet Corporation Operating Metrics

FY, 2016

Patents Issued


Patents Pending

Show all operating metrics

Insulet Corporation Market Value History

Insulet Corporation Revenue Breakdown

Insulet Corporation's Web-traffic and Trends

Insulet Corporation Online and Social Media Presence

Insulet Corporation Company Life and Culture

You may also be interested in